33.64
price up icon1.82%   0.60
after-market Handel nachbörslich: 32.70 -0.94 -2.79%
loading
Schlusskurs vom Vortag:
$33.04
Offen:
$32.92
24-Stunden-Volumen:
1.27M
Relative Volume:
0.63
Marktkapitalisierung:
$4.13B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-6.3954
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
+0.72%
1M Leistung:
+8.45%
6M Leistung:
-28.49%
1J Leistung:
-38.50%
1-Tages-Spanne:
Value
$32.66
$34.38
1-Wochen-Bereich:
Value
$32.63
$34.38
52-Wochen-Spanne:
Value
$29.31
$61.38

Cytokinetics Inc Stock (CYTK) Company Profile

Name
Firmenname
Cytokinetics Inc
Name
Telefon
(650) 624-3000
Name
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
498
Name
Twitter
@Cytokinetics
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CYTK's Discussions on Twitter

Vergleichen Sie CYTK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CYTK
Cytokinetics Inc
33.64 4.13B 18.47M -589.53M -399.80M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-24 Eingeleitet Barclays Overweight
2025-02-07 Eingeleitet Citigroup Buy
2025-01-22 Eingeleitet Stifel Buy
2024-11-08 Eingeleitet RBC Capital Mkts Outperform
2024-08-13 Herabstufung Goldman Buy → Neutral
2024-01-24 Herabstufung UBS Buy → Neutral
2024-01-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-11-09 Eingeleitet Goldman Buy
2023-11-07 Eingeleitet B. Riley Securities Buy
2023-08-15 Eingeleitet SVB Securities Outperform
2023-02-17 Eingeleitet BofA Securities Neutral
2022-12-23 Bestätigt Needham Buy
2022-12-20 Eingeleitet Truist Buy
2022-10-11 Eingeleitet UBS Buy
2022-01-28 Eingeleitet Goldman Buy
2021-12-22 Eingeleitet Oppenheimer Outperform
2021-12-10 Eingeleitet JP Morgan Overweight
2021-10-07 Eingeleitet Jefferies Buy
2021-03-12 Eingeleitet Wolfe Research Outperform
2021-02-18 Eingeleitet Barclays Overweight
2021-01-20 Bestätigt H.C. Wainwright Buy
2020-10-29 Eingeleitet Goldman Neutral
2020-07-10 Eingeleitet Raymond James Strong Buy
2020-05-05 Eingeleitet Mizuho Buy
2020-04-09 Hochstufung Morgan Stanley Equal-Weight → Overweight
2018-09-21 Eingeleitet Cantor Fitzgerald Overweight
2018-09-10 Fortgesetzt Morgan Stanley Equal-Weight
2017-11-22 Bestätigt Morgan Stanley Overweight
2017-11-22 Herabstufung Needham Strong Buy → Buy
2017-11-21 Bestätigt H.C. Wainwright Buy
2017-07-31 Eingeleitet Morgan Stanley Overweight
2017-03-08 Eingeleitet Rodman & Renshaw Buy
2017-02-06 Hochstufung Needham Buy → Strong Buy
2016-12-16 Eingeleitet Cantor Fitzgerald Overweight
2016-07-28 Bestätigt Needham Buy
2015-11-10 Bestätigt FBR Capital Outperform
2015-11-09 Bestätigt ROTH Capital Buy
2015-07-24 Bestätigt MLV & Co Buy
2014-12-31 Bestätigt ROTH Capital Buy
2014-11-04 Hochstufung MLV & Co Hold → Buy
2014-04-28 Bestätigt Needham Buy
Alle ansehen

Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten

pulisher
Jun 17, 2025

Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Awards 140,000 Shares Worth $2.9M in Employee Inducement GrantsSee Exercise Price - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 16, 2025

Cytokinetics CEO Robert Blum sells $169,000 in stock By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire

Jun 16, 2025
pulisher
Jun 14, 2025

Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 11, 2025

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program | CYTK Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - The Manila Times

Jun 10, 2025
pulisher
Jun 09, 2025

JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | CYTK Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Cytokinetics (CYTK) Target Price Cut by JPMorgan Analyst | CYTK Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | C - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire

Jun 09, 2025
pulisher
Jun 06, 2025

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - mx.advfn.com

Jun 06, 2025
pulisher
Jun 06, 2025

Shareholders That Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 05, 2025

Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion By Investing.com - Investing.com Nigeria

Jun 04, 2025
pulisher
Jun 04, 2025

Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion - Investing.com India

Jun 04, 2025
pulisher
Jun 02, 2025

Cetera Investment Advisers Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jun 01, 2025
pulisher
May 30, 2025

Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Mizuho - Defense World

May 30, 2025
pulisher
May 30, 2025

Recognizing Hypertrophic Cardiomyopathy in Women: Addressing Misdiagnosis - HCPLive

May 30, 2025
pulisher
May 29, 2025

Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | C - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cytokinetics (CYTK) Gets Price Target Reduction from Mizuho Anal - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cytokinetics to Participate in the Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Cytokinetics Management Reveals Latest Updates at Jefferies Healthcare ConferenceLive Webcast Available - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | CYTK Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating - marketscreener.com

May 29, 2025
pulisher
May 28, 2025

Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com

May 28, 2025
pulisher
May 27, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire

May 27, 2025
pulisher
May 21, 2025

Cytokinetics at RBC Conference: Strategic Insights on Drug Development By Investing.com - Investing.com Canada

May 21, 2025
pulisher
May 20, 2025

Protect Your Investment: Contact Levi & Korsinsky About the Cytokinetics, Incorporated (CYTK) Investigation - ACCESS Newswire

May 20, 2025
pulisher
May 20, 2025

BNP Paribas Financial Markets Trims Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World

May 20, 2025
pulisher
May 19, 2025

Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com

May 19, 2025
pulisher
May 18, 2025

Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM T - GuruFocus

May 18, 2025
pulisher
May 18, 2025

Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM Treatment | CYTK Stock News - GuruFocus

May 18, 2025
pulisher
May 18, 2025

Cytokinetics Presents Additional Data Related to Aficamten at th - GuruFocus

May 18, 2025
pulisher
May 18, 2025

Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics - Nasdaq

May 18, 2025
pulisher
May 16, 2025

Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

Cytokinetics (NASDAQ:CYTK) Upgraded at Cantor Fitzgerald - Defense World

May 16, 2025
pulisher
May 16, 2025

Cytokinetics Grants $1.2M in Equity Awards: New Hires Signal Growth in Cardiovascular Drug Development - Stock Titan

May 16, 2025
pulisher
May 16, 2025

Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from Needham & Company LLC - Defense World

May 16, 2025
pulisher
May 15, 2025

Insider Sell: Muna Bhanji Sells 1,454 Shares of Cytokinetics Inc (CYTK) - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Cytokinetics to Host Symposium on Contemporary Landscapes in Mus - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | C - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | CYTK Stock News - GuruFocus

May 15, 2025

Finanzdaten der Cytokinetics Inc-Aktie (CYTK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cytokinetics Inc-Aktie (CYTK) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Malik Fady Ibraham
EVP Research & Development
Jun 17 '25
Sale
32.91
2,000
65,820
140,610
Blum Robert I
President & CEO
Jun 16 '25
Sale
33.80
5,000
169,000
403,108
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):